Trial Information
Inclusion Criteria:
1. Patients 18 years of age with a definite diagnosis of multiple myeloma.
2. Patients have been on a steady dose of INTRON®A for at least 6 weeks and have
tolerated it (randomized study only), or patients who within six weeks of starting
INTRON®A become intolerant (tolerability sub-study only)
3. Informed consent obtained
Exclusion Criteria:
- a) Patients with refractory Multiple Myeloma. b) Treatment with any investigational drug
within 30 days of entry to this protocol.
c) Subjects who are pregnant, nursing, or of reproductive potential and who are not
practising an effective means of contraception.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Principal Investigator
Ray Powles, FRCP, FRCpath
Investigator Role:
Principal Investigator
Investigator Affiliation:
Royal Marsden NHS Foundation Trust
Authority:
United Kingdom: Research Ethics Committee
Study ID:
1871
NCT ID:
NCT00323505
Start Date:
March 2001
Completion Date:
December 2004
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell